These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 17160046)

  • 1. Bring the magic back to the bullets.
    Nat Biotechnol; 2006 Dec; 24(12):1489. PubMed ID: 17160046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amgen asks judge for speedy ruling in patent case.
    Nephrol News Issues; 1999 Dec; 13(12):14. PubMed ID: 11984928
    [No Abstract]   [Full Text] [Related]  

  • 3. Path to approval proves rocky for copycat biodrugs.
    Wadman M
    Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
    [No Abstract]   [Full Text] [Related]  

  • 4. HHS: POUFA reauthorization good for Americans.
    FDA Consum; 2002; 36(5):5. PubMed ID: 12412536
    [No Abstract]   [Full Text] [Related]  

  • 5. Moving goalposts--regulatory oversight of antibacterial drugs.
    Brenner R; Ellis-Grosse EJ; Echols R
    Nat Biotechnol; 2006 Dec; 24(12):1515-20. PubMed ID: 17160053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

  • 7. Barnyard biotech--lame duck or golden goose?
    Powell K
    Nat Biotechnol; 2003 Sep; 21(9):965-7. PubMed ID: 12949546
    [No Abstract]   [Full Text] [Related]  

  • 8. Investing in risk management.
    Fiscus PW
    Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
    [No Abstract]   [Full Text] [Related]  

  • 9. Will this experiment work?
    Kadlec D
    Time; 2003 Jul; 162(1):80-1. PubMed ID: 14584341
    [No Abstract]   [Full Text] [Related]  

  • 10. Millennium mergers bring pipeline.
    Dove A
    Nat Biotechnol; 1999 Dec; 17(12):1151. PubMed ID: 10585700
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibiotics--an investment worth making?
    Christoffersen RE
    Nat Biotechnol; 2006 Dec; 24(12):1512-4. PubMed ID: 17160052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA launches priority vouchers for neglected-disease drugs.
    Waltz E
    Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
    [No Abstract]   [Full Text] [Related]  

  • 13. Stepping up to the plate.
    Nat Immunol; 2008 Jan; 9(1):1. PubMed ID: 18087245
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibiotic bill doesn't GAIN enough ground.
    Ambrose PG
    Nat Med; 2011 Jul; 17(7):772. PubMed ID: 21738147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotech's next big blowup?
    Stires D
    Fortune; 2002 Mar; 145(6):154. PubMed ID: 11913033
    [No Abstract]   [Full Text] [Related]  

  • 16. The policy outlook from the Hill.
    Vastag B
    Nat Biotechnol; 2007 Jan; 25(1):13-6. PubMed ID: 17211381
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 18. Forging a new path. New law offers incentives to develop antibiotics.
    Lee J
    Mod Healthc; 2013 Feb; 43(5):8-9. PubMed ID: 23437480
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotechnology. Mixed reactions to merger.
    Gershon D
    Nature; 1990 Feb; 343(6260):681. PubMed ID: 2304541
    [No Abstract]   [Full Text] [Related]  

  • 20. The biotech drug market.
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.